FTRE logo

Fortrea Holdings Inc.

FTRE
Healthcare|Biotechnology|US
$21.96
+1.50 (+7.33%)
Cash / Share
$2.31
Next Earnings Report
Feb 25, 2027
EPS est. $0.19 · Revenue est. $674.5M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (17)

Nov 2026
Est. completion
P1Healthy Adult Participants
A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395
NCT07820891n=24
Nov 2026
Est. completion
P3APDS
Pediatric Patients Aged 4 to 11 Years With APDS
NCT05438407n=15
Dec 2026
Est. completion
NARenal Impairment After Cardiac Surgery
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
NCT07017933n=124
Jan 2027
Est. completion
P3Neovascular Age-related Macular Degeneration
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918n=825
Jan 2027
Est. completion
P3Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
NCT06706817n=181
Apr 2027
Est. completion
Atrial Fibrillation
Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation
NCT06083012n=186
May 2027
Est. completion
P1Systemic Lupus Erythematosus
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806n=72
Jun 2027
Est. completion
P3Severe Asthma
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779n=310
Sep 2027
Est. completion
Colorectal Cancer
First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
NCT06398743n=416
Feb 2028
Est. completion
P3Duchenne Muscular Dystrophy
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05933057n=138
Apr 2028
Est. completion
P1P2Colorectal Cancer (Diagnosis)
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
NCT07244705n=66
Jul 2028
Est. completion
P3APDS
Pediatric Patients Aged 1 to 6 Years With APDS
NCT05693129n=16
Oct 2028
Est. completion
P1P2B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219n=83
Jun 2029
Est. completion
P2P3Colorectal Cancer
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
NCT07219238n=175
Dec 2029
Est. completion
P2Duchenne Muscular Dystrophy
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
NCT06769633n=18
Aug 2030
Est. completion
P3Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
NCT07516132n=850
Sep 2032
Est. completion
P4Chronic Lymphocytic Leukaemia
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970n=60

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Apr 2026
P3
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06223958

Recent Press Releases

Fortrea Reports Third Quarter 2026 Results
Oct 29, 2026 · GlobeNewsWire
Fortrea to Participate in Jefferies Global Healthcare Conference
Oct 27, 2026 · GlobeNewsWire
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Oct 22, 2026 · GlobeNewsWire
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Oct 19, 2026 · GlobeNewsWire
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Oct 5, 2026 · GlobeNewsWire
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Sep 10, 2026 · GlobeNewsWire
Fortrea to Participate in September Investor Conferences
Sep 10, 2026 · GlobeNewsWire
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
Sep 2, 2026 · GlobeNewsWire

SEC Filings (67)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Sep 30, 20268-KMaterial eventDocumentIndex
Sep 10, 20268-KMaterial eventDocumentIndex
Jul 29, 202610-QQuarterly reportDocumentIndex
Jul 29, 20268-KMaterial eventDocumentIndex
Jul 14, 20268-KMaterial eventDocumentIndex
Jun 26, 20268-KMaterial eventDocumentIndex
Jun 12, 20268-KMaterial eventDocumentIndex
May 5, 202610-QQuarterly reportDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 27, 2026ARSAnnual report to holdersDocumentIndex
Apr 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 27, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 20, 20258-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Sep 22, 20258-KMaterial eventDocumentIndex
Aug 29, 2025S-8Employee stock planDocumentIndex
Aug 29, 2025S-8Employee stock planDocumentIndex
Aug 27, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 13, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 6, 202510-QQuarterly reportDocumentIndex
Aug 6, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 6, 20258-KMaterial eventDocumentIndex
Aug 5, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jul 29, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jul 17, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jul 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jun 12, 20258-KMaterial eventDocumentIndex
Jun 12, 20258-A12BDocumentIndex
Jun 12, 20258-KMaterial eventDocumentIndex
Jun 11, 20258-KMaterial eventDocumentIndex